Roche Launches Ventana HER2 Dual ISH CDx for the Identification of Breast and Gastric Cancer

 Roche Launches Ventana HER2 Dual ISH CDx for the Identification of Breast and Gastric Cancer

Roche Launches Ventana HER2 Dual ISH CDx for the Identification of Breast and Gastric Cancer

 Shots:

  • Roche’s Ventana HER2 Dual ISH DNA Probe Cocktail assay is used to detect HER2 biomarker in breast and gastric cancer patients receiving Herceptin (trastuzumab)
  • The approval of Ventana HER2 Dual ISH assay supports Roche’s personalized healthcare sector by providing techniques to diagnose breast and gastric cancer
  • The Ventana HER2 assay is fully automated on BenchMark IHC/ISH instruments providing results on the same day & can be read using light microscopy, launched in EU, the Middle East, Africa, Latin America & Asia Pacific with its expected regulatory submission to FDA 

Click here to read full press release/ article | Ref: Roche | Image: Ignition Dg

Tuba Khan

Tuba Khan is Senior Editor at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in the Life sciences industry. She covers Biopharma, MedTech, and Digital health segments. Tuba also has an experience of digital and social media marketing and runs the campaigns independently. She can be contacted on tuba@pharmashots.com

Related post